亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Use of Pyroglutamyl-Glutamyl-Prolyl Amide (Eep) for Neurological and Neurobehavioral Disorders

*Abstract: A tri-peptide drug for treatment of neurological and neurobehavioral disorders of a mammal, such drug being derived from the following formula: pGlu-X-Pro-NH 2 , wherein the internal amino acid (X) is a non-histadine amino acid. Methods of treatment of neurological disorders using the tri-peptide, including as an adjunct, synergist or stand-alone therapy, in oral, parenteral, intranasal, transcutaneous, or rectal forms.

*Principal Investigation: Name: Robert Lloyd
Department:

Name: Albert Pekary
Department:

Name: Albert Pekary
Department:

Name: Albert Sattin
Department:

Name: Albert Sattin
Department:

附加资料: Patent Number: US6475989B1
Application Number: US1998169657A
Inventor: Sattin, Albert | Pekary, Albert E. | Lloyd, Robert L.
Priority Date: 9 Oct 1997
Priority Number: US6475989B1
Application Date: 9 Oct 1998
Publication Date: 5 Nov 2002
IPC Current: A61K003806 | C07K0005097 | A61K003800
US Class: 5140175 | 514018 | 530331
Title: Use of pyroglutamyl-glutamyl-prolyl amide (EEP) for neurological and neurobehavioral disorders
Usefulness: Use of pyroglutamyl-glutamyl-prolyl amide (EEP) for neurological and neurobehavioral disorders
Summary: For the treatment of depression, schizophrenia and affective disorders (claimed) e.g. anxiety and mood disorders. Also useful for the treatment of neuromuscular weakness, spinal cord trauma, spasticity, dementia, Alzheimer's disease, somatization disorders, psychosomatic disorders, functional bowel disorders, epileptic disorders, sleep disorders and loss of motoric or cognitive functions resulting from spinal cord or brain stem injuries.
Novelty: Treatment of neurological and neurobehavioral disorders e.g. depression involves use of a composition comprising a tri-peptide or its salt

欲了解更多信息，请点击这里